Epstein-Barr virus infection induces bone resorption in apical periodontitis via increased production of reactive oxygen species
| Autor: | Maja Miletic, Miroslav Andric, Jelena Milasin, Slavko Mojsilović, Aleksandra Knezevic, Aleksandar Jakovljevic, Katarina Beljic-Ivanovic |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
Human cytomegalovirus Epstein-Barr Virus Infections Herpesvirus 4 Human Osteoclasts Inflammation Bone resorption Pathogenesis 03 medical and health sciences 0302 clinical medicine Osteoprotegerin medicine Animals Humans Bone Resorption Periodontitis B-Lymphocytes Periapical periodontitis Receptor Activator of Nuclear Factor-kappa B biology Chemistry RANK Ligand Epithelial Cells 030206 dentistry General Medicine Models Theoretical medicine.disease 3. Good health 030104 developmental biology RANKL Immunology biology.protein medicine.symptom Reactive Oxygen Species Periapical Periodontitis |
| Zdroj: | Medical Hypotheses |
| ISSN: | 0306-9877 |
| DOI: | 10.1016/j.mehy.2016.06.020 |
| Popis: | Chronic inflammatory processes in periapical tissues caused by etiological agents of endodontic origin lead to apical periodontitis. Apart from bacteria, two herpesviruses, Epstein-Barr virus (EBV) and Human cytomegalovirus (HCMV) are recognized as putative pathogens in apical periodontitis. Although previous reports suggest the involvement of EBV in the pathogenesis of apical periodontitis, its exact role in periapical bone resorption has not yet been fully elucidated. We hypothesize that EBV infection in apical periodontitis is capable of inducing periapical bone resorption via stimulation of reactive oxygen species (ROS) overproduction. Increased levels of ROS induce expression of receptor activator of nuclear factor kappa B (NF-kappa B) ligand (RANKL). RANKL binding to receptor activator of nuclear factor kappa B (RANK) present on the surface of preosteoclasts induces their maturation and activation which consequently leads to bone resorption. The potential benefit of antiviral and antioxidant-based therapies in periapical bone resorption treatment remains to be assessed. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect